The major hypothesis for this study was that:
1) There would be no significant difference in the effects of the three treatment regimens on pain, muscle fatigue, muscle endurance, activity limitation, disability, fear-avoidance behaviour, pain self-efficacy belief, belief of consequence of back pain and general health status in patients with long-term mechanical LBP.
1.4.2 Sub Hypotheses
The following sub-hypotheses were tested in this study:
1. There would be no significant difference in the pain intensity of participants in the McKenzie Protocol Group (MPG) across weeks 0, 4 and 8 of the study.
2. There would be no significant difference in the static muscle endurance of participants in the MPG across weeks 0, 4 and 8 of the study.
3. There would be no significant difference in the dynamic muscle endurance of participants in the MPGacross weeks 0, 4 and 8 of the study.
4. There would be no significant difference in the muscle fatigue of participants in the
MPG across weeks 0, 4 and 8 of the study.
5. There would be no significant difference in the activity limitation of participants in the MPG across weeks 0, 4 and 8 of the study.
6. There would be no significant difference in the disability of participants in the MPG across weeks 0, 4 and 8 of the study.
7. There would be no significant difference in the fear-avoidance behaviour of participants in the MPG across weeks 0, 4 and 8 of the study.
8. There would be no significant difference in the pain self-efficacy belief of participants in the MPG across weeks 0, 4 and 8 of the study.
9. There would be no significant difference in the belief of the consequences of back pain of participants in the MPG across weeks 0, 4 and 8 of the study.
10. There would be no significant difference in the general health status of participants in the MPG across weeks 0, 4 and 8 of the study.
11. There would be no significant difference in the pain intensity of participants in the McKenzie Protocol plus Static Back Endurance Exercise Group (MPSBEEG) across weeks 0, 4 and 8 of the study.
12. There would be no significant difference in the static muscle endurance of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
13. There would be no significant difference in the dynamic muscle endurance of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
14. There would be no significant difference in the muscle fatigue of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
15. There would be no significant difference in the activity limitation of participants in
the MPSBEEG across weeks 0, 4 and 8 of the study.
16. There would be no significant difference in the disability of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
17. There would be no significant difference in the fear-avoidance behaviour of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
18. There would be no significant difference in the pain self-efficacy belief of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
19. There would be no significant difference in the belief of the consequences of back pain of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
20. There would be no significant difference in the general health status of participants in the MPSBEEG across weeks 0, 4 and 8 of the study.
21. There would be no significant difference in the pain intensity of participants in the McKenzie Protocol plus Dynamic Back Endurance Exercise Group (MPDBEEG) across weeks 0, 4 and 8 of the study.
22. There would be no significant difference in the static muscle endurance of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
23. There would be no significant difference in the dynamic muscle endurance of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
24. There would be no significant difference in the muscle fatigue of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
25. There would be no significant difference in the activity limitation participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
26. There would be no significant difference in the disability of participants in the
MPDBEEG across weeks 0, 4 and 8 of the study.
27. There would be no significant difference in the fear-avoidance behaviour of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
28. There would be no significant difference in the pain self-efficacy belief of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
29. There would be no significant difference in the belief of the consequences of back pain of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
30. There would be no significant difference in the general health status of participants in the MPDBEEG across weeks 0, 4 and 8 of the study.
31. There would be no significant difference in the effect of the three treatment regimens on pain intensity at week four of the study.
32. There would be no significant difference in the effect of the three treatment regimens on static muscle endurance at week four of the study.
33. There would be no significant difference in the effect of the three treatment regimens on dynamic muscle endurance at week four of the study.
34. There would be no significant difference in the effect of the three treatment regimens on muscle fatigue at week four of the study.
35. There would be no significant difference in the effect of the three treatment regimens on activity limitation at week four of the study.
36. There would be no significant difference in the effect of the three treatment regimens on disability at week four of the study.
37. There would be no significant difference in the effect of the three treatment regimens on fear-avoidance behaviour at week four of the study.
38. There would be no significant difference in the effect of the three treatment regimens on pain self-efficacy belief at week four of the study.
39. There would be no significant difference in the effect of the three treatment regimens on belief of consequences of back pain at week four of the study.
40. There would be no significant difference in the effect of the three treatment regimens on general health status at week four of the study.
41. There would be no significant difference in the effect of the three treatment regimens on pain intensity at week eight of the study.
42. There would be no significant difference in the effect of the three treatment regimens on static muscle endurance at week eight of the study.
43. There would be no significant difference in the effect of the three treatment regimens on dynamic muscle endurance at week eight of the study.
44. There would be no significant difference in the effect of the three treatment regimens on muscle fatigue at week eight of the study.
45. There would be no significant difference in the effect of the three treatment regimens on activity limitation at week eight of the study.
46. There would be no significant difference in the effect of the three treatment regimens on disability at week eight of the study.
47. There would be no significant difference in the effect of the three treatment regimens on fear-avoidance behaviour at week eight of the study.
48. There would be no significant difference in the effect of the three treatment regimens on pain self-efficacy belief at week eight of the study.
49. There would be no significant difference in the effect of the three treatment regimens
on belief of consequences of back pain at week eight of the study.
50. There would be no significant difference in the effect of the three treatment regimens on general health status at week eight of the study.